| |
| | Abbott Laboratories Announces European Approval of Uprima |
 | | Abbott Park, Illinois, May 30, 2001 /PSA Rising/ - Abbott Laboratories announced today that it has received a marketing authorization from the European Commission for UPRIMA for the treatment of erectile dysfunction (ED). |
 | | Abbott Laboratories holds exclusive and non-exclusive rights to UPRIMA in markets outside the United States and Canada, having licensed the product from TAP Pharmaceutical Products, Inc., a joint venture between Abbott Laboratories and Takeda Chemical Industries Ltd. TAP licensed apomorphine hydrochloride tablets (sublingual) for erectile dysfunction from Pentech Pharmaceuticals, Inc. |
 | | Abbott Laboratories is a global, diversified health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals, nutritionals, and medical products, including devices and diagnostics. |
| www.psa-rising.com /wiredbird/abbott-uprimaj0601.htm (533 words) |
|